ALK Inhibitors for Acquired Resistance: Zykadia and Alectinib

Ceritinib and Alectinib in Relapsed ALK+ NSCLCПодробнее

Next-generation ALK inhibitors: treatment sequencing and resistanceПодробнее

ALK TKI Side Effects and Acquired Resistance - 2022 Program: Targeted Therapies ForumПодробнее

Dr. Shaw Discusses LDK378 and Alectinib (AF802) for ALK-Positive NSCLCПодробнее

Dr. Velcheti on Potential of Alectinib in Frontline ALK-Positive NSCLCПодробнее

Treating With ALK Inhibitors in NSCLCПодробнее

Alectinib in ALK-Mutated NSCLCПодробнее

Ceritinib and Other Second Generation ALK Inhibitors for Acquired Resistance in ALK-Positive NSCLCПодробнее

Should a Second Generation ALK Inhibitor be First Line Therapy for Patients with ALK-Positive NSCLC?Подробнее

Next-Generation ALK Inhibitors for NSCLCПодробнее

Available Therapies for ALK-Rearranged NSCLCПодробнее

Updated Data from Phase 2 Study of Alectinib in ALK–Positive Non–Small–Cell Lung CancerПодробнее

Dr. Shaw on Alectinib as First-Line Therapy in Lung CancerПодробнее

Current & Emerging Approaches to Acquired Resistance for ALK/ROS1Подробнее

Next generation inhibitors help overcome problems of resistance in ALK positive lung cancerПодробнее

Introduction to ALK inhibitorsПодробнее

Managing Resistance to ALK Inhibitors in NSCLCПодробнее

Dr. Govindan on the Potential for AlectinibПодробнее

Dr. Gandhi Discusses the Role of Alectinib in ALK+ Lung CancerПодробнее